Verrica Pharmaceuticals INC 8-K filings

Verrica Pharmaceuticals announced Q2 2026 financial results, highlighting record demand for YCANTH with a 28.3% sequential increase in dispensed units, while also reporting a net loss and increased R&D spending for pipeline development.

Verrica Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders, approving an equity incentive plan and ratifying auditor selection.

Verrica Pharmaceuticals announced first quarter 2026 financial results, highlighting record demand for YCANTH and progress in its clinical development programs.

Verrica Pharmaceuticals announced the appointment of Charles Frantzreb to its Board of Directors and approved significant equity compensation for its CEO and Interim CFO.

Verrica Pharmaceuticals announced a $50 million private placement to retire debt and extend its cash runway into mid-2027, alongside board changes.

Verrica Pharmaceuticals reported a significant increase in third-quarter 2025 revenue, driven by YCANTH sales and milestone payments, alongside positive regulatory feedback for its pipeline assets.

Verrica Pharmaceuticals Inc. announced a return to profitability in Q2 2025, driven by strong YCANTH sales growth and a significant milestone payment, while also regaining Nasdaq compliance.

Verrica Pharmaceuticals Inc. is actively working to regain compliance with Nasdaq's minimum bid price requirement following a delisting notice, implementing a reverse stock split and showing progress towards continued listing.

Verrica Pharmaceuticals Inc. will implement a 1-for-10 reverse stock split effective July 24, 2025, to consolidate its common stock and adjust outstanding shares.

Verrica Pharmaceuticals Inc. announced a second amendment to its collaboration agreement with Torii Pharmaceutical, securing $18 million in non-dilutive milestone payments and advancing a global Phase 3 clinical trial for YCANTH in common warts.

Verrica Pharmaceuticals Inc. has entered into a sixth amendment to its credit agreement, securing a waiver from lenders regarding 'going concern' qualifications for upcoming financial statements, signaling ongoing financial challenges.

Verrica Pharmaceuticals Inc. announced that its stockholders approved all four proposals at the 2025 Annual Meeting, including the election of three directors, executive compensation, auditor ratification, and authorization for a potential reverse stock split.

Verrica Pharmaceuticals announces its Q1 2025 financial results, highlighting $3.4 million in YCANTH revenue and progress in its late-stage pipeline.

Christopher G. Hayes resigns from his role as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary of Verrica Pharmaceuticals, effective April 30, 2025.

Verrica Pharmaceuticals announces the appointment of Gavin Corcoran to its Board of Directors, effective immediately.

Verrica Pharmaceuticals announces its Q4 and full year 2024 financial results, showcasing growth in YCANTH dispensed applicator units and progress in its late-stage pipeline.

Verrica Pharmaceuticals obtains a waiver from its lenders for specific financial covenants related to going concern qualifications.

Verrica Pharmaceuticals received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Verrica Pharmaceuticals has appointed David Zawitz as Chief Operating Officer and increased the number of shares available under its 2024 Inducement Plan.

Verrica Pharmaceuticals has announced a public offering to raise approximately $42 million through the sale of common stock, pre-funded warrants, and accompanying Series A and B warrants.

Verrica Pharmaceuticals has initiated a public offering of its common stock and warrants, while also providing updates on its commercial strategy and clinical pipeline.

Verrica Pharmaceuticals announced a leadership transition, including a new CEO and interim CFO, alongside its third-quarter 2024 financial results, which included negative net product revenue and a focus on cost reduction.

Verrica Pharmaceuticals is temporarily non-compliant with Nasdaq listing rules due to a director's resignation, triggering a cure period.

Verrica Pharmaceuticals is reducing its workforce by 47 employees to streamline operations and cut costs, incurring approximately $1.0 million in expenses.

Verrica Pharmaceuticals' Chief Financial Officer, Terence Kohler, has resigned, effective October 4, 2024, to pursue a new business opportunity.

Verrica Pharmaceuticals has entered into a Release Agreement and a Consulting Agreement with its former Chief Commercial Officer, Joe Bonaccorso, as previously disclosed.

Verrica Pharmaceuticals announces the resignation of its Chief Commercial Officer, Joe Bonaccorso, effective August 30, 2024, with a transition plan involving a consulting agreement.

Verrica Pharmaceuticals announced its second quarter 2024 financial results, highlighted by $4.9 million in YCANTH revenue and positive preliminary Phase 2 results for VP-315 in basal cell carcinoma.

Verrica Pharmaceuticals has amended its credit agreement, delaying the start of its revenue test to December 31, 2024, waiving going concern qualifications, and increasing the exit fee.

Verrica Pharmaceuticals has amended its credit agreement, delaying the start of its revenue test for YCANTH to September 30, 2024, and incurring a $500,000 amendment fee.